Factor VIIa, recombinant (NovoSeven RT)
Also known as AryoSeven, coagulation factor VIIa, eptacog alfa (activated), factor 7a, NovoSeven, Novo-Seven, or NovoSeven room temperature stable.
General information
Class/mechanism: Recombinant factor VIIa; complexes with tissue factor and can activate coagulation factors X to Xa and IX to IXa, which results in conversion of prothrombin to thrombin, and fibrinogen to fibrin to form a fibrin clot. There is still uncertainty about the precise mechanism, and activation of factor X on platelet surfaces may also play an important role. Clinical applications include use for patients with inhibitors to factors VIII and IX, as can be the case in hemophilia A and hemophilia B.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found on page 6 of the Factor VIIa, recombinant (NovoSeven RT package insert[1]
- Factor VIIa, recombinant (NovoSeven RT) patient drug information (UpToDate)[4]